Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Weather
Wake County is under alert.
Program
On WRAL at 11: Storms rolling through Sunday night. We'll tell you if they'll affect your Labor Day plans in the morning
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Novartis Ag ADR
(NY:
NVS
)
120.89
+0.47 (+0.39%)
Official Closing Price
Updated: 7:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Novartis Ag ADR
< Previous
1
2
3
4
5
6
7
8
9
...
28
29
Next >
Eyes On Novartis, Gilead, Bristol Myers As FDA Weighs Risks Vs. Benefits Of Approved CAR T-Cell Therapies
November 29, 2023
Tuesday, the FDA said it received reports of patients developing T-cell malig
Via
Benzinga
Exposures
Product Safety
3 Healthcare Stocks to Pick Up Before the Year-End Rally
November 28, 2023
Explore the potential of healthcare stocks as the U.S. charges ahead with $4.3 trillion in healthcare spending
Via
InvestorPlace
Novartis Outlines Pure-Play Strategy Progress After Generics Business Spin-Off
November 28, 2023
Novartis AG (NYSE: NVS) has outlined the progress made in delivering its pure-play strategy, focused on four core therapeutic areas (Cardiovascular-Renal-Metabolic, Immunology, Neuroscience, Oncology),...
Via
Benzinga
Olema Stock Has Soared 551% This Year. Its CEO Thinks It's Still Undervalued.
November 22, 2023
The company is working on treatments for breast cancer in a market worth $15 billion, according to the CEO.
Via
Investor's Business Daily
Week In Review: Legend Partners DLL3 CAR-T Candidate With Novartis In $1.2 Billion Deal
November 18, 2023
Legend Biotech partnered its DLL3 CAR-T candidates to Novartis in a $1.2 billion agreement, with $100 million offered upfront. Novartis will own worldwide rights to develop, manufacture, and...
Via
Talk Markets
How Is The Market Feeling About Novartis?
November 10, 2023
Via
Benzinga
Apple, AMD, Palantir Earnings On Deck This Week As Market Seeks Positive Catalysts In Fed Decision Week
October 30, 2023
S&P 500 earnings is expected to grow in Q3, reversing a four-quarter slide, as the reporting season enters its third week.
Via
Benzinga
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
Novartis Hikes Its Earnings Outlook For The Third Time This Year
October 24, 2023
The company also beat third-quarter expectations after spinning off its Sandoz unit.
Via
Investor's Business Daily
Diversifying Your Portfolio With Plant-Based Options
November 16, 2023
Investors see profit potential in the plant-based market due to rising consumer demand, ESG focus, and the growth of vegan products in various industries, including pharmaceuticals. However, market...
Via
Talk Markets
Looking for Stocks to Buy? Here Are the Companies Johnson & Johnson Is Betting the Most On
November 16, 2023
Unsurprisingly, Johnson & Johnson's top investments are all in the healthcare sector.
Via
The Motley Fool
Verve Loses A Third Of Its Value As Safety Concerns Plague Its Gene-Editing Drug
November 13, 2023
Patients had big decreases in LDL cholesterol. But there were some side effects.
Via
Investor's Business Daily
3 Spectacular High-Yield Dividend Stocks to Buy in November
November 05, 2023
Income investors should find plenty to like with these stocks.
Via
The Motley Fool
Novartis' Rare Kidney Disease Candidate Aces Late-Stage Study
October 30, 2023
Novartis AG (NYSE: NVS) released topline results from the interim analysis of the ongoing pivotal Phase 3 ALIGN study of atrasentan in patients with IgA nephropathy (IgAN). IgAN is a major cause of...
Via
Benzinga
Earnings Outlook For Novartis
October 23, 2023
Via
Benzinga
Are Your Eyes At Grave Risk? FDA Issues Dangerous Warning Over Popular Drops From CVS, Target, Cardinal Health And More
October 28, 2023
The U.S.
Via
Benzinga
Exposures
Product Safety
3 No-Brainer Stocks to Buy for Under $100 Right Now
October 28, 2023
A couple of these stocks might not be available for under $100 for too much longer.
Via
The Motley Fool
2 Green Flags and 1 Red Flag for Novartis Stock
October 27, 2023
The Swiss pharmaceutical company just posted strong Q3 numbers and is going through some big changes.
Via
The Motley Fool
7 Undervalued Stocks to Buy Before Everyone Else
October 26, 2023
Buy these undervalued stocks while they trade at a significant discount compared to their intrinsic valuations.
Via
InvestorPlace
Sanofi Stock Relative Strength Rating Jumps To 84: One To Watch
October 24, 2023
Additionally, Sanofi stock has a decent 83 Composite Rating out of 99, and an 80 Earnings Per Share Rating.
Via
Investor's Business Daily
Novartis Ag (NVS) Q3 2023 Earnings Call Transcript
October 24, 2023
NVS earnings call for the period ending September 30, 2023.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Avenue Z Hires Leading Digital Media and Technology Executive David Corchado to Lead Team in Global Strategy
October 24, 2023
--News Direct--
Via
News Direct
US Stock Futures Surge Ahead Of Microsoft, Google Earnings: Analyst Says 'Magnificent Seven' Unlikely To See Tesla-Like Volatility After Results
October 24, 2023
Buoyed by earnings optimism, stocks appear on track for a positive open on Tuesday after the tech-heavy Nasdaq Composite Index snapped a four-day losing streak in the previous session. The uptick in...
Via
Benzinga
Topics
Bonds
Stocks
Exposures
Debt Markets
US Equities
Novartis Q3: Earnings Beat, Raised Operating Profit Outlook & More
October 24, 2023
Novartis AG (NYSE: NVS) reported
Via
Benzinga
Topics
Earnings
Exposures
Financial
Amazon, Alphabet, Meta, Intel Q3 Earnings This Week: Will Mega-Caps Shatter Forecasts And Revive Market?
October 23, 2023
Factset data indicates that out of the 17% of the S&P 500 companies that have reported so far, 73% have reported positive EPS surprises.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
7 Healthcare Stocks to invest in for a Healthy Future
October 20, 2023
Considering today's economic uncertainty and market turns, healthcare stocks may be one of the few winning sectors. Here are the winners.
Via
InvestorPlace
2 Biotech Stocks That Could Make You Richer
October 17, 2023
These two well-known drugmakers still have some growth fuel in their seemingly empty tanks.
Via
The Motley Fool
3 Unstoppable Stocks to Buy and Hold for Decades
October 17, 2023
These stocks can be pillars for your long-term portfolio, and investing in all three offers excellent diversification.
Via
The Motley Fool
Why Top 1% Biotech MoonLake Just Surged Within Striking Distance Of A Breakout
October 16, 2023
MoonLake says it's skin-disease treatment showed improved promise in a 24-week testing update.
Via
Investor's Business Daily
RayzeBio Is A New Contender in Radiopharmaceutical Arena, Will Attract Prominent Entities: JP Morgan
October 10, 2023
JP Morgan has initiated coverage on RayzeBio Inc (NASDAQ: RYZB), representing a pure-play opportunity in the radiopharmaceutical space.
Via
Benzinga
AbbVie Stock Moves Higher With Rising Relative Strength
October 10, 2023
A Relative Strength Rating upgrade for AbbVie shows improving technical performance. Will it continue?
Via
Investor's Business Daily
< Previous
1
2
3
4
5
6
7
8
9
...
28
29
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.